Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERT: Combination Cefazolin With Ertapenem for MSSA Bacteremia
NCT04886284Phase 2Recruiting
- Start
- May 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ertapenem in Staphylococcus aureus bacteremia (SAB), Staphylococcus aureus septicemia (SAB), staphylococcal sepsis, Staphylococcus aureus infective endocarditis (SAIE). Started May 2024; status: recruiting.
02
Drugs
ertapenem
03
Conditions
Staphylococcus aureus bacteremia (SAB)Staphylococcus aureus septicemia (SAB)staphylococcal sepsisStaphylococcus aureus infective endocarditis (SAIE)
Beyond the preview
Go deeper on NCT04886284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886284.